ro.com glp 1 Ro introduces one-month $199 Wegovy® new patient offer and discounted Body membership Ro Launches Weight Loss Program
Description
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Curious about GLP-1s in Canada
As GLP-1 receptor agonists, these peptide drugs mimic the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite [9]
Evidence-based UK guidance.
95% CI 0.89 to 0.44), and WC (SMD 0.40
HELPS DIGESTION & SUSTAINS ENERGY Bloating, irregular digestion, and energy dips can be challenges when following a GLP-1 lifestyle
